← Back to headlines
H.C. Wainwright Initiates Coverage of Generate Biomedicines
H.C. Wainwright has initiated coverage of Generate Biomedicines (GENB) with a 'Buy' rating. This new analyst report offers a positive investment perspective on the biotechnology firm.
20 Apr, 00:11 — 20 Apr, 00:11
Sources
Showing 1 of 1 sources
